AUS
NZ
UK
CA
USA
IND
.jpg)
Starpharma Holdings Limited (ASX:SPL) has announced a fully underwritten 1 for 7.5 renounceable pro-rata entitlement offer priced at $0.57 per share, targeting to raise around $32 million. The funds will support the completion of the first-in-human and dose escalation phases of its DEP® HER2-Lu Phase 1 trial, development of innovative dendrimer-based oncology assets, and cover working capital and transaction expenses. Canaccord Genuity (Australia) Limited is appointed as lead manager and underwriter.
Key Highlights
- Starpharma Holdings Limited (SPL) is raising approximately $32 million through a fully underwritten entitlement offer.
- Eligible shareholders can subscribe for 1 new share for every 7.5 fully paid ordinary shares held as of 20 July 2026.
- Shares are offered at $0.57 each; the offer is renounceable, allowing entitlements to be traded on the ASX.
- Net proceeds will fund the completion of DEP® HER2-Lu Phase 1 first-in-human and dose escalation stages, pipeline expansion of dendrimer-based oncology assets, and working capital.
- The entitlement offer closes at 5:00 pm Melbourne time on 4 August 2026, with results announced on 11 August 2026.
- Eligible shareholders include those registered by 7:00 pm Melbourne time on 20 July 2026 with addresses in Australia, New Zealand, Singapore, Hong Kong, the UK, or Luxembourg.
Starpharma’s Focus on Dendrimer-Based Oncology and Capital Requirements
Starpharma Holdings Limited is a biopharmaceutical company specialising in targeted dendrimer-based oncology therapeutics. Its lead candidate, DEP® HER2-Lu, marks a significant advancement in its innovative cancer treatment pipeline. The $32 million capital raise is pivotal as the company progresses to clinical validation of its DEP® platform in human trials, underscoring its commitment to expanding precision medicine solutions for unmet cancer treatment needs.
The entitlement offer allows existing shareholders to maintain their ownership percentage while providing vital funding for clinical advancement. Starpharma’s focus on dendrimer technology highlights its strategic commitment to precision oncology drug development. The timing of this capital raise aligns with the company’s transition into human clinical testing phases for its flagship DEP® asset.
DEP® HER2-Lu Phase 1 Clinical Trial: First-In-Human and Dose Escalation Stages
Proceeds from the entitlement offer will primarily fund the completion of the first-in-human and dose escalation stages of the DEP® HER2-Lu Phase 1 clinical trial. This milestone represents a critical step in Starpharma’s drug development, transitioning from preclinical studies to human subjects. Phase 1 oncology trials assess safety, tolerability, and initial efficacy, laying the groundwork for subsequent clinical phases.
Completing these early human trials is essential to validate the DEP® HER2-Lu therapeutic approach and generate clinical data to guide regulatory and development strategies. HER2-targeted therapies are established in oncology, and Starpharma’s dendrimer-based mechanism offers a potentially unique treatment modality. Specific details on dosing cohorts, patient numbers, or timelines were not disclosed. Successful completion will pave the way for Phase 2 trials and may enhance the company’s commercial outlook.
Pipeline Expansion: Developing Novel Dendrimer-Based Oncology Assets
Beyond DEP® HER2-Lu, Starpharma will allocate funds to accelerate development of additional targeted dendrimer-based oncology candidates, broadening its therapeutic pipeline. This strategy reflects the company’s intent to diversify beyond a single clinical program. Although specific targets or tumor types were not detailed, the capital raise will support preclinical and early-stage development efforts.
This expansion demonstrates management’s confidence in the dendrimer platform’s versatility across multiple cancer indications, reducing single-asset risk and enhancing value creation opportunities. Investments may include research, preclinical studies, and exploratory clinical trials, ensuring sustained momentum across Starpharma’s oncology portfolio.
Entitlement Offer Details: 1 for 7.5 Shares at $0.57 Each
The entitlement offer grants eligible shareholders the right to subscribe for 1 new fully paid ordinary share for every 7.5 shares held as of 7:00 pm Melbourne time on 20 July 2026. The issue price is set at $0.57 per share. Shareholders may also apply for additional shares up to 100% above their entitlement, subject to legal allowances. The renounceable nature permits shareholders to sell their entitlements on the ASX or transfer them to third parties.
This pro-rata structure ensures equitable treatment of shareholders, offering proportional investment opportunities. Shareholders not acting by the 5:00 pm Melbourne time deadline on 4 August 2026 will be deemed to have renounced their entitlements. The fully underwritten offer, led by Canaccord Genuity (Australia) Limited, guarantees the full $32 million capital raise regardless of shareholder uptake.
Underwriting and Offer Administration by Canaccord Genuity and Computershare
Canaccord Genuity (Australia) Limited serves as lead manager and underwriter, providing a full underwriting commitment that secures the $32 million proceeds. This mitigates capital raising risks and assures shareholders of the offer’s success. Computershare Investor Services Pty Limited manages share registry functions, including distribution of entitlement documents and processing applications and payments. Eligible shareholders can access personalised entitlement details and payment instructions at www.computersharecas.com.au/sploffer, with BPAY® available for applications. Support is available via 1300 850 505 (Australia) or +61 3 9415 4000 (international).
Eligibility and Geographic Restrictions for Shareholders
Eligible participants are shareholders recorded by 7:00 pm Melbourne time on 20 July 2026 with registered addresses in Australia, New Zealand, Singapore, Hong Kong, the United Kingdom, or Luxembourg. U.S. persons or those acting for U.S. accounts are excluded due to regulatory compliance. This limitation aligns with U.S. securities laws and the company’s capital raising strategy. Shareholders in other jurisdictions should contact the share registry for eligibility clarification.
The entitlement offer is conducted without a prospectus or product disclosure statement under section 708AA of the Corporations Act 2001 (Cth), as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2026/98, streamlining the capital raising process for eligible companies. The geographic restrictions reflect regulatory and strategic considerations.
Entitlement Offer Timeline and Important Dates
The offer was announced on 15 July 2026, with the Appendix 3B and Cleansing Notice lodged the same day. The ex-date was 17 July 2026, with entitlement trading commencing on a deferred basis from that date. The record date is 20 July 2026 at 7:00 pm Melbourne time. Offer documents were sent to eligible shareholders on 23 July 2026, coinciding with the offer opening.
The entitlement offer closes at 5:00 pm Melbourne time on 4 August 2026. Entitlement trading ends at 4:00 pm on 28 July 2026. Results will be announced on 11 August 2026, with share allotment occurring the same day. Dates are indicative and may change with underwriter consent, subject to regulatory compliance. Extensions may affect the issue and quotation dates.
Offer Booklet and Shareholder Resources
Full terms, conditions, risk factors, and shareholder obligations are detailed in the Offer Booklet, available at www.computersharecas.com.au/sploffer and https://starpharma.com/entitlement-offer. Shareholders are encouraged to review the booklet carefully before participating. Investor relations inquiries can be directed to [email protected] or via the company website.
Shareholders should consult professional advisers to assess suitability of participation. The announcement clarifies that information provided is general and does not constitute financial advice. Cooling-off rights do not apply to shares acquired under the entitlement offer.
Capital Deployment: Clinical Development, Pipeline Growth, and Working Capital
In addition to clinical development and pipeline expansion, a portion of net proceeds will fund working capital and transaction costs. Working capital supports operational expenses including staff, laboratories, regulatory compliance, and administration. Specific allocations between categories were not disclosed.
Transaction costs cover fees for Canaccord Genuity, Computershare, legal, accounting, and ASX regulatory charges, deducted from gross proceeds. This balanced capital allocation supports both near-term clinical objectives and ongoing operational needs.
Regulatory Compliance and Corporations Act Adherence
The entitlement offer complies with section 708AA of the Corporations Act 2001 (Cth), as amended by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2026/98, allowing streamlined pro-rata offers without a prospectus. The company has lodged an Appendix 3B and Cleansing Notice with the ASX, ensuring full disclosure. Restrictions on U.S. investors align with the U.S. Securities Act of 1933, with securities not registered for U.S. offering.
